{"schema_version":"secwatch.filing_event.v1","accession":"0001663577-25-000033","form_type":"8-K","ticker":"SKVI","cik":"0001085277","company_name":"SKINVISIBLE, INC.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:02.896102+00:00","generated_at":"2026-05-27T13:17:47.800435+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Skinvisible licensee Quoin reports positive Netherton Syndrome clinical results; $5M milestone payment upon approval","bullets":["Quoin's QRX003 (using Invisicare) showed 'severe' to 'mild' improvement after 6 weeks in Netherton Syndrome studies.","FDA cleared a whole-body study at Northwestern University; no adverse events reported to date.","Clinical trials expanded to UK, Ireland, and Saudi Arabia; product licensed in 60 countries.","Skinvisible to receive $5M milestone payment plus ongoing royalties upon FDA or EU approval.","Skinvisible actively seeking partnerships for transdermal obesity therapies and other formulations."],"urls":{"canonical":"https://secwatch.observer/filing/0001663577-25-000033","json":"https://secwatch.observer/filing/0001663577-25-000033.json","markdown":"https://secwatch.observer/filing/0001663577-25-000033.md","text":"https://secwatch.observer/filing/0001663577-25-000033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/0001663577-25-000033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1085277/000166357725000033/skvi8k_012325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T13:17:47.800435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}